| Full samplea (n = 21) | Subgroupb (n = 11) |
---|---|---|
Age (yr) | 71 (41-87) | 73 (55-83) |
Male gender, % | 11 (52.4) | 5 (45.5) |
APACHE II score | 24 (17-39) | 25 (20-39) |
SOFA score | 8 (3-17) | 9 (3-16) |
Source of infection, % | Â | Â |
   Lung | 11 (52.4) | 3 (27.3) |
   Abdomen | 6 (28.6) | 4 (36.4) |
   Urinary tract | 3 (14.3) | 3 (27.3) |
   Line | 1 (4.7) | 1 (9.0) |
Vasopressors/inotropes dosec | Â | Â |
   Norepinephrine, mcg/min | 10; 10 (2-40) | 6; 10 (2-25) |
   Dobutamine, mcg/kg/min | 4; 5 (2.5-10) | 2; 3.7 (2.5-5) |
Sedation/analgesic dosec | Â | Â |
   Midazolam, mg/hr | 7; 2 (2-4) | 4; 2 (2-4) |
   Fentanyl, mcg/hr | 8; 100 (50-400) | 4; 100(50-400) |
Human recombinant activated protein C, % | 14.3 | 27.3 |
Renal replacement therapy, % | 33.3 | 27.3 |
Red blood cell storage time (days) | 32 (21-39) | 32 (22-39) |
In-hospital mortality, % | 47.6 | 45.6 |